Funding
BLOOD, HEART, LUNG, TRANSITION
This study was, in part, funded by National Institutes of Health (NIH) Agreement 1OT2HL156812-01. Specifically, the ACTIV-4B trial was supported by Other Transition Authorities from the National Heart, Lung, and Blood Institute (NHLBI). Grantee institutions included the University of Pittsburgh; the University of Illinois Chicago; and the Brigham and Women’s Hospital. The trial drugs and matching placebo were donated by the Bristol Myers Squibb–Pfizer Alliance.